Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
Status:
Completed
Trial end date:
2019-10-17
Target enrollment:
Participant gender:
Summary
Determine the safety, tolerability and maximum tolerated dose of anetumab ravtansine (BAY
94-9343) in combination with pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 in subjects with
mesothelin-expressing predominantly epithelial mesothelioma or nonsquamous non-small-cell
lung cancer.